Company / Net Income
AVADEL PHARMACEUTICALS PLC Net Income History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$48.8M
FY2024
5-year range
-$160.3M / $7.0M
FY2020-FY2024
Trend
+69.5%
vs FY2023
Sector context
#81 of 216
Health Care
What the data says
At -$49M, AVADEL PHARMACEUTICALS PLC's net income ranks #81 of 216 in the Health Care sector. Net Income returned to growth in FY2024 after 3 years of decline, reaching -$49M.
Based on SEC 10-K filings.
-$49M in FY2024.
Improved from -$137M to -$49M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#81 of 216 in Health CareTop 37% of 216This company -$48.8M Sector average $454.3M
▼
-110.7% below sector average
Key checks
Key Insights
- In FY2024, net income increased 69.5% year-over-year.
- Ranks #81 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2017.
- Lowest net income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$48.8M | +69.5% |
| FY2023 | -$160.3M | -16.6% |
| FY2022 | -$137.5M | -77.8% |
| FY2021 | -$77.3M | -1200.3% |
| FY2020 | $7.0M | +121.2% |
| FY2019 | -$33.2M | +65.1% |
| FY2018 | -$95.3M | -239.6% |
| FY2017 | $68.3M | +265.4% |
| FY2016 | -$41.3M | -198.8% |
| FY2015 | $41.8M | +148.9% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026